PMVP logo

PMV Pharmaceuticals, Inc.

PMVP
Healthcare|Biotechnology|US
$1.26
-0.01 (-1.18%)
DCF Value
$0.65
Tangible Book / Share
$1.34
Cash / Share
$1.49
Next Earnings Report
Nov 11, 2026
EPS est. -$0.34
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Sep 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Dec 2026
Est. completion
P1P2Advanced Solid Tumor
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750n=300
Mar 2027
Est. completion
P1TP53 Y220C Mutation
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625n=14
Aug 2027
Est. completion
P1Myelodysplastic Syndrome
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
NCT06616636n=24

Recent Press Releases

Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
Nov 4, 2026 · GlobeNewsWire
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
Aug 31, 2026 · GlobeNewsWire
PMV Pharma Announces Proposed Public Offering of Securities
Aug 31, 2026 · GlobeNewsWire
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Aug 31, 2026 · GlobeNewsWire
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Aug 14, 2026 · GlobeNewsWire

SEC Filings (55)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 5, 20268-KMaterial eventDocumentIndex
Sep 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 2, 20268-KMaterial eventDocumentIndex
Sep 2, 2026424B5Offering prospectusDocumentIndex
Aug 31, 2026424B3Offering prospectusDocumentIndex
Aug 31, 2026424B5Offering prospectusDocumentIndex
Aug 31, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Jul 28, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 10, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 5, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 22, 2026ARSAnnual report to holdersDocumentIndex
Apr 22, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 22, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 6, 2026S-8Employee stock planDocumentIndex
Mar 6, 20268-KMaterial eventDocumentIndex
Mar 6, 202610-KAnnual reportDocumentIndex
Mar 4, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 9, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Nov 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 27, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Sep 23, 2025SC 13GPassive 5%+ stakeDocumentIndex
Sep 10, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Jun 9, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 9, 202510-QQuarterly reportDocumentIndex
May 9, 20258-KMaterial eventDocumentIndex
Apr 25, 2025ARSAnnual report to holdersDocumentIndex